Sangamo Therapeutics, Inc.SGMONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank53
3Y CAGR-25.1%
5Y CAGR-10.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-25.1%/yr
vs +21.4%/yr prior
5Y CAGR
-10.3%/yr
Recent deceleration
Acceleration
-46.6pp
Decelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $104.91M | -5.9% |
| 2024 | $111.52M | -52.4% |
| 2023 | $234.06M | -6.3% |
| 2022 | $249.90M | +8.3% |
| 2021 | $230.82M | +27.8% |
| 2020 | $180.65M | +23.8% |
| 2019 | $145.92M | +27.0% |
| 2018 | $114.87M | +74.8% |
| 2017 | $65.73M | +0.2% |
| 2016 | $65.62M | - |